Kimberly Gentile
CIK 1704186 · SVP, Clinical Operations · last filed 2026-03-03
Kimberly Gentile is a SVP, Clinical Operations who has filed 28 SEC Form 4 insider transactions across 2 companies since 2017. The most recent filing, for BHVN, was dated Mar 3, 2026. Across all open-market trades the lifetime net is −$6.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.1M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.15M
2
28
-$6.10M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BHVN | SVP, Clinical Operations | 101,513 | $11.28 | $1.15M | -$6.10M | 26 | 2026-03-03 |
| Biohaven Pharmaceutical Holding Co Ltd. (BHVNw) Delisted | SVP, Clinical Operations | 0 | — | — | $0 | 1 | 2022-10-03 |
Recent Filings
28 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-03 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2026-01-07 | BHVN | Mixed | +1,794 | -$19.4K | EDGAR |
| 2025-01-07 | BHVN | Mixed | +1,794 | -$75.6K | EDGAR |
| 2024-01-04 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2023-11-06 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2022-10-05 | — | Mixed | +95,969 | $18.7K | |
| 2022-10-03 | Biohaven Pharmaceutical Holding Co Ltd. (BHVNw) Delisted | Disp (D) | −11,653 | -$1.73M | EDGAR |
| 2022-01-07 | BHVN | Mixed | +1,950 | -$222.9K | EDGAR |
| 2021-11-26 | BHVN | Mixed | +2,012 | -$200.8K | EDGAR |
| 2021-01-08 | BHVN | Mixed | +2,003 | -$145.7K | EDGAR |